From theory to therapy.Creating homeostatic harmony by downregulation of oxidative stress response pathways.
Company Allegro is redefining the treatment of ocular diseases with integrin inhibition therapy. more…
Science Our mechanism of action (MOA) focuses on the disruption of integrin functions. more…
Pipeline Allegro seeks to uncover groundbreaking treatments for eye care patients who have limited or no options, or who inadequately respond to existing therapies. more…
Therapeutic Areas Allegro focuses on ocular diseases with unmet needs such as intermediate dry AMD, DME and dry eye disease. more…